NCT00315380 Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
| NCT ID | NCT00315380 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Eosinophilic Granulomatosis With Polyangiitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2006-04 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2006-04 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.
Eligibility Criteria
Inclusion Criteria: Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study. Parent or guardian willing to provide informed consent, if applicable Exclusion Criteria: \- Inability to give informed consent and to sign the consent form
Contact & Investigator
Peter A. Merkel, MD, MPH
STUDY CHAIR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT00315380 clinical trial?
This trial is open to participants of all sexes, studying Eosinophilic Granulomatosis With Polyangiitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00315380 currently recruiting?
Yes, NCT00315380 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Pennsylvania to inquire about joining.
Where is the NCT00315380 trial being conducted?
This trial is being conducted at San Diego, United States, Denver, United States, Boston, United States, Rochester, United States and 9 additional locations.
Who is sponsoring the NCT00315380 clinical trial?
NCT00315380 is sponsored by University of Pennsylvania. The principal investigator is Peter A. Merkel, MD, MPH at University of Pennsylvania. The trial plans to enroll 700 participants.